Results 201 to 210 of about 32,790 (255)

Antibody-drug conjugates in recurrent or metastatic HNSCC: relevant targets, clinical development, and future prospects. [PDF]

Front Immunol
Zhao H, Zhang S, Wang F, Yu P, Li J, Jia L, He P, Liu R, Zhang J, Wang K, Han R, Huangfu H.   +11 more
europepmc   +1 more source

Antibody-drug conjugates in cancer therapy: do we need biomarkers? A comprehensive review. [PDF]

Cancer Metastasis Rev
Lei L, Zheng YB, Tang SC.
europepmc   +1 more source

Pharmacologic modulation of topoisomerase I inhibitors

, 2001
openaire   +1 more source

Topoisomerase I inhibitors for the treatment of brain tumors

Expert Review of Anticancer Therapy, 2008
Patients with primary malignant brain tumors have a poor prognosis. Standard treatment includes surgical resection, radiation therapy and chemotherapy. Topoisomerase I inhibitors such as topotecan and irinotecan (CPT-11) represent one class of chemotherapy drugs that have been used in this disease.
Lynn, Feun, Niramol, Savaraj
openaire   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

TOPOISOMERASE-I INHIBITORS IN GYNECOLOGIC TUMORS

Hematology/Oncology Clinics of North America, 1999
The first section of this article reviews recent studies that have clarified both the cellular role of topoisomerase I and the mechanisms of cytotoxicity of the topoisomerase inhibitors, the camptothecins. Different analogs of this new class of antitumor drug have been studied using various dose schedules in the treatment of refractory or recurrent ...
P, Haluska, E, Rubin, C F, Verschraegen
openaire   +2 more sources

Edotecarin: A Novel Topoisomerase I Inhibitor

Clinical Colorectal Cancer, 2005
Edotecarin (PHA-782615; formerly J-107088) is a derivative of NB-506, an indolocarbazole antitumor agent. It is a novel inhibitor of topoisomerase I that induces single-strand DNA cleavage more effectively than NB-506 or camptothecin (CPT) and at different DNA sequences. The DNA-topoisomerase I complexes induced by edotecarin are more stable than those
M Wasif, Saif, Robert B, Diasio
openaire   +2 more sources

Synthesis of nitrated indenoisoquinolines as topoisomerase I inhibitors

Bioorganic & Medicinal Chemistry Letters, 2004
AbstractFor Abstract see ChemInform Abstract in Full Text.
Andrew, Morrell, Smitha, Antony, Glenda, Kohlhagen, Yves, Pommier, Mark, Cushman   +4 more
openaire   +2 more sources

Toxicity of the topoisomerase II inhibitors

Expert Opinion on Drug Safety, 2005
The topoisomerase I inhibitors represent a class of antineoplastic agents with a wide spectrum of activity against malignancies. Currently available topo-isomerase I inhibitors are derivatives of the parent compound, camptothecin. Irinotecan is most active against gastrointestinal (GI) tumours, and has predominantly GI and haematological toxicities ...
openaire   +3 more sources

Synthesis and Evaluation of Terbenzimidazoles as Topoisomerase I Inhibitors

Journal of Medicinal Chemistry, 1995
The synthesis and pharmacological activity of a series of terbenzimidazoles are described. The ability of these derivatives to induce DNA cleavage in the presence of topoisomerase I was evaluated in vitro. These analogs were also assayed for their cytotoxicity in RPMI 8402 cells and the camptothecin-resistant CPT-K5 cells. In addition the potential for
SUN Q, GATTO, BARBARA, YU C, LIU A, LIU LF, LAVOIE EJ   +5 more
openaire   +2 more sources

Degradation of Topoisomerase I Induced by Topoisomerase I Inhibitors Is Dependent on Inhibitor Structure but Independent of Cell Death

Molecular Pharmacology, 1999
DNA topoisomerase I (top I) is the target of the antitumor drug camptothecin (CPT) and its analogs. CPT induces dose- and time-dependent degradation of top I. Degradation of top I also occurs in a CPT-resistant cell line and, therefore, is not a consequence of cell death. Top I degradation is preceded by the appearance of a high molecular weight ladder
Q, Fu, S W, Kim, H X, Chen, S, Grill, Y C, Cheng   +4 more
openaire   +2 more sources